AAAAAA

   
Results: 1-25 | 26-44
Results: 1-25/44
Future for ovarian cancer screening: Novel markers from emerging technologies of transcriptional profiling and proteomics
Authors: Mills, GB Bast, RC Srivastava, S
Citation: Gb. Mills et al., Future for ovarian cancer screening: Novel markers from emerging technologies of transcriptional profiling and proteomics, J NAT CANC, 93(19), 2001, pp. 1437-1439
Heregulin-induced apoptosis is mediated by down-regulation of Bcl-2 and activation of caspase-7 and is potentiated by impairment of protein kinase C alpha activity
Authors: Le, XF Marcelli, M McWatters, A Nan, BC Mills, GB O'Brian, CA Bast, RC
Citation: Xf. Le et al., Heregulin-induced apoptosis is mediated by down-regulation of Bcl-2 and activation of caspase-7 and is potentiated by impairment of protein kinase C alpha activity, ONCOGENE, 20(57), 2001, pp. 8258-8269
Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer
Authors: Rivera, E Valero, V Syrewicz, L Rahman, Z Esteva, FL Theriault, RL Rosales, MM Booser, D Murray, JL Bast, RC Hortobagyi, GN
Citation: E. Rivera et al., Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer, J CL ONCOL, 19(6), 2001, pp. 1716-1722
2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology
Authors: Bast, RC Ravdin, P Hayes, DF Bates, S Fritsche, H Jessup, JM Kemeny, N Locker, GY Mennel, RG Somerfield, MR
Citation: Rc. Bast et al., 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology, J CL ONCOL, 19(6), 2001, pp. 1865-1878
2000 update of recommendations for the use of tumor markets in breast and colorectal cancer: Clinical practice guidelines for the American Society ofClinical Oncology (vol 19, pg 1865, 2001)
Authors: Bast, RC Ravdin, P Hayes, DF Bates, S Fritsche, H Jessup, JM Kemeny, N Locker, GY Mennel, RG Somerfield, MR
Citation: Rc. Bast et al., 2000 update of recommendations for the use of tumor markets in breast and colorectal cancer: Clinical practice guidelines for the American Society ofClinical Oncology (vol 19, pg 1865, 2001), J CL ONCOL, 19(21), 2001, pp. 4185-4188
Fluorescence spectroscopy for in vivo characterization of ovarian tissue
Authors: Brewer, M Utzinger, U Silva, E Gershenson, D Bast, RC Follen, M Richards-Kortum, R
Citation: M. Brewer et al., Fluorescence spectroscopy for in vivo characterization of ovarian tissue, LASER SURG, 29(2), 2001, pp. 128-135
Genomic structure and promoter characterization of an imprinted tumor suppressor gene ARHI
Authors: Luo, RZ Peng, HQ Xu, FJ Bao, JJ Pang, Y Pershad, R Issa, JPJ Liao, WSL Bast, RC Yu, YH
Citation: Rz. Luo et al., Genomic structure and promoter characterization of an imprinted tumor suppressor gene ARHI, BBA-GENE ST, 1519(3), 2001, pp. 216-222
High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: A new regimen for the treatment of advanced ovarian cancer
Authors: Donato, ML Gershenson, DM Wharton, JT Ippoliti, CM Aleman, AS Bodurka-Bevers, D Bevers, MW Burke, TW Levenback, CF Wolf, JK Freedman, RS Bast, RC Gajewski, JL Champlin, RE
Citation: Ml. Donato et al., High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: A new regimen for the treatment of advanced ovarian cancer, GYNECOL ONC, 82(3), 2001, pp. 420-426
Synergistic interaction between an anti-p185(HER-2) pseudomonas exotoxin fusion protein [scFv(FRP5)-ETA] and ionizing radiation for inhibiting growthof ovarian cancer cells that overexpress HER-2
Authors: Schmidt, M McWatters, A White, RA Groner, B Wels, W Fan, Z Bast, RC
Citation: M. Schmidt et al., Synergistic interaction between an anti-p185(HER-2) pseudomonas exotoxin fusion protein [scFv(FRP5)-ETA] and ionizing radiation for inhibiting growthof ovarian cancer cells that overexpress HER-2, GYNECOL ONC, 80(2), 2001, pp. 145-155
Regulation of invasion of epithelial ovarian cancer by transforming growthfactor-beta
Authors: Rodriguez, GC Haisley, C Hurteau, J Moser, TL Whitaker, R Bast, RC Stack, MS
Citation: Gc. Rodriguez et al., Regulation of invasion of epithelial ovarian cancer by transforming growthfactor-beta, GYNECOL ONC, 80(2), 2001, pp. 245-253
Genetic analysis of early- versus late-stage ovarian tumors
Authors: Shridhar, V Lee, J Pandita, A Iturria, S Avula, R Staub, J Morrissey, M Calhoun, E Sen, A Kalli, K Keeney, G Roche, P Cliby, W Lu, K Schmandt, R Mills, GB Bast, RC James, CD Couch, FJ Hartmann, LC Lillie, J Smith, DI
Citation: V. Shridhar et al., Genetic analysis of early- versus late-stage ovarian tumors, CANCER RES, 61(15), 2001, pp. 5895-5904
OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markersfor epithelial ovarian carcinoma - A critical appraisal
Authors: van Haaften-Day, C Shen, Y Xu, FJ Yu, YH Berchuck, A Havrilesky, LJ de Bruijn, HWA van der Zee, AGJ Bast, RC Hacker, NF
Citation: C. Van Haaften-day et al., OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markersfor epithelial ovarian carcinoma - A critical appraisal, CANCER, 92(11), 2001, pp. 2837-2844
Synergistic interaction between anti-p185(HER-2) ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2
Authors: Xu, FJ Leadon, SA Yu, YH Boyer, CM O'Briant, K Ward, K McWatters, A Zhao, XG Bae, DS DeSombre, K Zalutsky, MR Bast, RC
Citation: Fj. Xu et al., Synergistic interaction between anti-p185(HER-2) ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2, CLIN CANC R, 6(8), 2000, pp. 3334-3341
Anti-HER2 antibody and heregulin suppress growth of HER2-overexpressing human breast cancer cells through different mechanisms
Authors: Le, XF McWatters, A Wiener, J Wu, JY Mills, GB Bast, RC
Citation: Xf. Le et al., Anti-HER2 antibody and heregulin suppress growth of HER2-overexpressing human breast cancer cells through different mechanisms, CLIN CANC R, 6(1), 2000, pp. 260-270
Molecular approaches to management of epithelial ovarian cancer
Authors: Bast, RC Yu, Y Xu, FJ Le, XF Mills, GB
Citation: Rc. Bast et al., Molecular approaches to management of epithelial ovarian cancer, INT J GYN C, 10, 2000, pp. 2-7
Functional evidence for an ovarian cancer tumor suppressor gene on chromosome 22 by microcell-mediated chromosome transfer
Authors: Kruzelock, RP Cuevas, BD Wiener, JR Xu, FJ Yu, YH Cabeza-Arvelaiz, Y Pershouse, M Lovell, MM Killary, AM Mills, GB Bast, RC
Citation: Rp. Kruzelock et al., Functional evidence for an ovarian cancer tumor suppressor gene on chromosome 22 by microcell-mediated chromosome transfer, ONCOGENE, 19(54), 2000, pp. 6277-6285
High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer
Authors: Donato, ML Gershenson, D Ippoliti, C Wharton, JT Bast, RC Aleman, A Anderlini, P Gajewski, JG Giralt, S Molldrem, J Ueno, N Lauppe, J Korbling, M Boyer, J Bodurka-Bevers, D Bevers, M Burke, T Freedman, R Levenback, C Wolf, J Champlin, RE
Citation: Ml. Donato et al., High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer, BONE MAR TR, 25(11), 2000, pp. 1137-1140
Inhibition of growth-factor-induced phosphorylation and activation of protein kinase B/Akt by atypical protein kinase C in breast cancer cells
Authors: Mao, ML Fang, XJ Lu, YL LaPushin, R Bast, RC Mills, GB
Citation: Ml. Mao et al., Inhibition of growth-factor-induced phosphorylation and activation of protein kinase B/Akt by atypical protein kinase C in breast cancer cells, BIOCHEM J, 352, 2000, pp. 475-482
Lysophosphatidic acid prevents apoptosis in fibroblasts via G(i)-protein-mediated activation of mitogen-activated protein kinase
Authors: Fang, XJ Yu, SX LaPushin, R Lu, YL Furui, T Penn, LZ Stokoe, D Erickson, JR Bast, RC Mills, GB
Citation: Xj. Fang et al., Lysophosphatidic acid prevents apoptosis in fibroblasts via G(i)-protein-mediated activation of mitogen-activated protein kinase, BIOCHEM J, 352, 2000, pp. 135-143
Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A
Authors: Fang, XJ Yu, SX Lu, YL Bast, RC Woodgett, JR Mills, GB
Citation: Xj. Fang et al., Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A, P NAS US, 97(22), 2000, pp. 11960-11965
Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass
Authors: Hogdall, EVS Hogdall, CK Tingulstad, S Hagen, B Nustad, K Xu, FJ Bast, RC Jacobs, IJ
Citation: Evs. Hogdall et al., Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass, INT J CANC, 89(6), 2000, pp. 519-523
ARHI is the center of allelic deletion on chromosome 1p31 ovarian and breast cancers
Authors: Peng, HQ Xu, FJ Pershad, R Hunt, KK Frazier, ML Berchuck, A Gray, JW Hogg, D Bast, RC Yu, YH
Citation: Hq. Peng et al., ARHI is the center of allelic deletion on chromosome 1p31 ovarian and breast cancers, INT J CANC, 86(5), 2000, pp. 690-694
The human ARHI tumor suppressor gene inhibits lactation and growth in transgenic mice
Authors: Xu, FJ Xia, WY Luo, RZ Peng, HQ Zhao, SL Dai, JY Long, Y Zou, LL Le, WD Liu, JS Parlow, AF Hung, MC Bast, RC Yu, YH
Citation: Fj. Xu et al., The human ARHI tumor suppressor gene inhibits lactation and growth in transgenic mice, CANCER RES, 60(17), 2000, pp. 4913-4920
Differential signaling by an anti-p185(HER2) antibody and heregulin
Authors: Le, XF Vadlamudi, R McWatters, A Bae, DS Mills, GB Kumar, R Bast, RC
Citation: Xf. Le et al., Differential signaling by an anti-p185(HER2) antibody and heregulin, CANCER RES, 60(13), 2000, pp. 3522-3531
Alterations in oncogenes, tumor suppressor genes, and growth factors associated with epithelial ovarian cancers
Authors: Bast, RC Mills, GB
Citation: Rc. Bast et Gb. Mills, Alterations in oncogenes, tumor suppressor genes, and growth factors associated with epithelial ovarian cancers, METH MOL M, 39, 2000, pp. 37-48
Risultati: 1-25 | 26-44